Latest Shareholder Dilution News

Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Patagonia Lithium Ltd has announced a fully underwritten entitlement offer to raise approximately $2.68 million, aimed at advancing its drilling program in Argentina and updating its mineral resource estimates. The offer, supported by major shareholders, reflects confidence in the company’s Formentera Lithium Brine Project.

Koba Resources has issued over 11 million new shares and attached options to fund exploration at its Yarramba Uranium Project, signaling renewed momentum in its uranium ambitions.

Lodestar Minerals has issued a replacement proxy form to correct an omission in its original Notice of Meeting, ensuring shareholders can fully participate in the upcoming General Meeting.

Vanadium Resources Limited has raised A$1.2 million through an oversubscribed placement to support its near-term production ambitions and convert outstanding debt into equity, strengthening its balance sheet.

NOVONIX has entered a multi-tranche funding agreement with Yorkville Advisors to raise up to US$100 million through convertible debentures, supporting its Riverside facility build-out and commercial production ramp-up.

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Fat Prophets Global Contrarian Fund has announced a fully franked special dividend of 5 cents per share, reflecting strong investment performance. The dividend reinvestment plan offers shareholders a 2.5% discount on reinvested shares, signaling confidence in future growth.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

Barton Gold Holdings has revealed a preliminary A$26 million refurbishment plan for its Central Gawler Mill, aiming to restart production by the end of 2026 with significant cost and operational advantages.

Yugo Metals Limited has launched a $100,000 capital raising through a new options offer, aiming to bolster working capital while navigating significant geopolitical and operational challenges in Bosnia and Herzegovina.